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It  was  more  than  a  generation  ago  that  studies  from  the  laboratories  of 
MacDowell (1), Furth (2), and others first indicated that virus-induced leukemo- 
genesis in mice is under genetic control.  Much subsequent  study had demon- 
strated that a number of well-characterized Mendelian loci affect leukemogene- 
sis by what appear to be distinct effects at different steps between virus expres- 
sion  or  infection,  and  neoplasia.  For  example,  the Akv-1  and Akv-2  genes, 
discovered in a  study of hybrids of high spontaneous leflkemia incidence mice, 
AKR,  with  low  incidence strains,  e.g.  C57BL,  govern viral  induction  and/or 
expression  (3,  4).  The Fv-1  locus,  first described by Lilly  (5)  in  studies  with 
Friend leukemia virus (FV), ~ appears to affect in vivo and in vitro replication of 
all  naturally  occurring  C-type RNA  viruses  (6).  H-2  linked  genes  appear  to 
affect the course of virus-induced leukemogenesis, rather than the initial virus 
infection and replication  (7).  Progress in analyzing these genetic controls has 
made it apparent that further understanding of multigenic regulation of virus- 
induced leukemogenesis will require greater knowledge of gene-gene interac- 
tions. 
During the course of experiments dealing with H-2-1inked effects on resist- 
ance  to  radiation  leukemia  virus  (RadLV)-induced  leukemia,  one  strain, 
B10.AQR(n4),  was found to be highly susceptible to the disease.  This was  an 
unexpected result since this strain expresses the H-2D d allele,  which usually 
confers resistance to RadLV. In this study, evidence indicates that a single locus 
in the B10.AQR(n4) genome, distinct from other presently defined loci affecting 
virus-induced leukemogenesis, such as Fvl-, Fv-2, and H-2, confers susceptibil- 
ity to RadLV~induced tumorigenesis. The susceptible allele of this locus, which 
shall be defined as Srlv-1  (susceptibility to RadLV),  is dominantly expressed. 
* Supported in part by NIH grant AI 07757 and NIH contract CB 43941. 
Supported by a postdoctoral fellowship from the Damon Runyon-Walter Winchell Memorial 
Cancer Fund, DRG-30-F  for the period of 1974-1976, and by a NIH postdoctoral fellowship for 1976- 
1977. 
Abbreviations used in this paper: FV, Friend leukemia virus; Fv-1, gene governing relative 
spleen focus response to F-S strain of FV; Fv-2, gene governing relative spleen focus response to F- 
B strain of FV; r, resistance;  RadLV, radiation leukemia virus; s, susceptibility;  SFFV, spleen 
focus-forming virus; Srlv-1, susceptibility to radiation-leukemia  virus-1. 
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This system is particularly  interesting  because the Srlv-1  locus overrides the 
protection against neoplasia conferred by the H-2D d allele. 
Materials  and Methods 
Mice.  B10.AQR(nS)  mice were generously supplied by Dr.  Jan  Klein,  University of Texas 
Southwestern Medical School,  Dallas,  Texas.  All other mouse strains (Table II) were bred and 
maintained in our own colonies. 
Viruses.  RadLV preparations were cell-free extracts from virus-induced lymphoid tumors of 
C57BL/Ka mice, made as previously described (8-10).  FV preparations were kindly supplied by 
Dr.  Frank  Lilly,  Albert Einstein College of Medicine,  Bronx,  N.  Y.,  and Dr.  Bruce Chesebro, 
National Institutes of Health, Rocky Mountain Laboratory, Hamilton,  Mont. 
Virus Inoculation  and Scoring for Leukemogenesis.  All animals received RadLV intrathymi- 
tally at 3-6 wk of age and were scored for leukemogenesis after autopsy as described previously 
(8). 
H-2  Typing ofF2 Progeny.  Contract antiserum D-17  [(D1.C  x  AKR.M)F~  anti-DBA.1;  i.e., 
anti-H-2K  q] and an [(A.TL  x  B10.S(5R))F~ anti-B10.A; i.e., anti-H-2K  ~] antiserum raised in our 
laboratory were used to H-2 genotype F2 progeny by the hemagglutination assay (8,  11). 
Virus Susceptibility Test,  Mice were scored as being either susceptible or resistant at Fv-2 
according to the results of the spleen focus assay (12).  Mice were injected in the tail vein with 
various FV dilutions and killed 9-10 days later. Their spleens were removed and weighed, fixed in 
Bouin's  solution  for  about  3  h,  and  examined  for  macroscopic  foci.  Under  these  conditions, 
susceptible  mice  showed  markedly  enlarged  spleens  with  many  foci,  whereas  resistant  mice 
showed spleens of near normal size with no or very few foci. 
Results 
A  Single  Locus,  Srlv-1  Confers  Dominant  Susceptibility  to RadLV-Induced 
Neoplasia.  In the preceding publication (8), we showed that C57BL/10-derived 
congenic  strains  of mice  carrying  the  H-2D d  allele  are  resistant  to  RadLV- 
induced leukemogenesis, and that resistance is dominant.  One exception to this 
rule is strain B10.AQR(n4). As shown in Fig. 1, and Table I, this mouse strain is 
highly susceptible to the disease.  In addition,  [B10.AQR(n4)  ×  B10.A)F1  [sus- 
ceptible(s)  ×  resistant(r)]  mice  are  susceptible  to  RadLV=induced  neoplasia, 
demonstrating that susceptibility is dominant. 
The H-2 chromosome (H-2 ~1) carried by B10.AQR(n4) was derived by recom- 
bination  in a  (B10.A  x  T138)FI  heterozygote  (13,  14). The crossover occurred 
between the H-2K  and Ir-lA  loci,  such that  it derived the H-2Kq  allele from 
T138, and the Ir-lA k allele (and H-2D d allele) from B10.A. Progeny carrying the 
recombinant chromosome were backcrossed four times to strain  B10, and then 
intercrossed  to  establish  the  B10.AQR(n4)  line.  Since  8-15  backcrosses  are 
required to produce a  truly congenic line  (15),  intercrossing  after only 4 back- 
crosses to B10 potentially fixes T138-derived alleles at loci not linked to H-2. 
The  first  clue that  a  locus not  linked  to H-2  determined  susceptibility to 
RadLV-induced leukemogenesis came from studies  with strain  B10.AQR(nS). 
This  strain  was derived from the eighth  backcross generation,  and  would be 
expected to carry less of the genome foreign to the original  B10 stock. Table I 
compares the mortality incidence of B10.AQR(nS) mice with B10.AQR(n4) ani- 
mals. It is clear that the n8 generation,  like other strains expressing the H-2D ~ 
allele, is resistant to neoplasia. This finding suggests that a locus not linked to 
H-2  confers  susceptibility  to  RadLV-induced  leukemogenesis,  and  that  the 
dominant  allele  carred  by  B10.AQR(n4)  has  been  lost  after  four  additional 
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FIG.  1.  Percent  survival to  leukemogenesis  vs.  weeks  after intrathymic inoculation of 
RadLV into B10.AQR(n4) (H-2D d, see Table I) compared to the average incidence for eight 
other strains havingH-2D d genotype [B10.T(6R), B10.S(7R), B10.A, B10.A(3R), B10.A(5R), 
B10.A(18R), B10.HTT, and B10.D2]. None of the eight strains used to calculate the average 
leukemia incidence had a  survival curve significantly different from the average curve. 
B10.AQR(n4) had a survival curve typical of other highly susceptible strains, such as B10.S 
and B10.G(8). 
TABLE  I 
BI O.AQR(n4) Carries A  Dominant Locus Conferring Susceptibility to 
RadL V-Induced  Neoplasia 
Mean sur-  Leukemia 
viral time  incidence  No. of ani- 
Strain  after  22 wk after 
mals tested  RadLV in-  RadLV in- 
oculation  oculation 
wk  % 
B10.AQR(n4)  48  17  79 
B10.AQR(n8)  8  32*  0 
B10.A  59  31"  19 
[B10,AQR(n4)  ×  B10.A]F1  18  18  78 
* Values may be higher since animals not leukemic at termination of experi- 
ment (approximately 40 wk) would probably have survived longer. 
Formal genetic proof that  a  single locus determining susceptibility to  the 
neoplasia  is  not  linked  to  H-2  was  achieved  by  segregation  analysis. 
[B10.AQR(n4)  x  B10.A]F1  mice were intercrossed, and the F2 generation ana- 
lyzed. Antisera specific for the H-2K q product [expressed by B10.AQR(n4)] (see 
Table II) and the H-2K k produce (expressed by B10.A) (see Table II) permitted 
identification of the H-2 haplotype(s) carried by the progeny. 
Table III shows the expected leukemia incidence of [B10.AQR(n4) × B10.A]F2 
mice as predicted by three different modes of inheritance of susceptibility to 
RadLV. Susceptibility may resul.t from (a) a dominantly expressed H-2-1inked 
locus; (b) a single, dominantly expressed locus (Srlv-1) not linked to H-2; or (c) D.  MERUELO,  M.  LIEBERMAN,  B.  DEAK,  AND  H.  O.  McDEVITT 
TABLE  II 
Haplotype Origin @Region Carried by Strains Used in the Present 
Work 
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Strain  H-2 haplotype 
Haplotype origin of region 
H-2 
K  A  B  J  E  C  S  G  D 
B10.A  H-2"  k  k  k  k  k  I *d 
B10.AQR  H -2~1  q  I  k  k  k  k  d 
B10. S  H-2"  s  s  s  s  s  s 
B10.G  H-2 e  q  q  q  q  q  q 
B10.T(6R)  1-1-2 v2  q  q  q  q  q  q 
B10.S(7R)  H-2 t2  s  s  s  s  s  s 
B10.A(3R)  H-2 ~  b  b  b  b  [  k  d 
B10.A(5R)  H-2 ~5  b  b  b  [  k  k  d 
B10.A(18R)  H-2 t  b  b  b  b  b  b 
B10.HTT  H-2 '~  s  s  s  s  I  k  k 
B10.D2  1-'1-2  d  d  d  d  d  d  d 
d  d  d 
d  d  d 
8  8  8 
q  q  q 
qi?id 
s  s  l  d 
d  d  d 
d  d  d 
bi?id 
k  k  d 
d  d  d 
* Vertical bar indicates crossover position. 
TABLE HI 
Outcome of an F2 Segregation Analysis Designed to Determine the Number and 
H-2-Linkage of Gene(s) Conferring Dominant Susceptibility to RadL V 
Hypothesis considered 
Postulated genot  ypes 
Mortality incidence 22 
wk aRer RadLV inoc- 
ulation 
Parent~  Fs  Expected  Observed 
No. of  Result 
mice  from 
t~ted  test 
One dominant H.2-1inked  locus confers  BI0.AQR: 
susceptibility  to  RadLV.  Thus  only  BI0.A: 
Fs mice of the 1"1-2  "~" genotype should  F~: 
be resistant to neoplasia. 
One  dominant,  non-H-2-1inked  locus  B10.AQR: 
(Srlv-l)  confers  susceptibility  to 
RadLV. Therefore, Fj offspring of all  B10.A: 
1"I-2 genotypel should be el, suscepti- 
ble and 1/4 resistant.  Fz: 
%  % 
H-2 *I~yl  1"1-2 ~J~*l  79  57  7 
H-2 °'"  H-2 °j°  19  60  10  P  < 0.006 (hypothe- 
H-2 ~I~"  1,1-2 ~v°  78  64  14  sis rejected) 
Stir.1 ~,  H-2 u~'  64  57  7  P  > 0.650 (hypothe- 
1.1-2 ,v,I  sis  not  rejected) 
8rlv-l"~"  1"1-2  ~"  64  60  10 
H.2.J. 
Srlv-I "~"  H.2 ~v°  64  64  14 
H-2 ~l~. 
Two  dominant,  non-H-2-1inked  loci  Stir.1 ~j 
(Stir-l,  Sdv-2)  confer susceptibility  B10.AQR:  Stir-2 ~°  H-2 ~vvt  75  57  7 
to RadLV.  FI mice of all 1"1-2  gono-  H-2 wv~l 
types  should  therefore  be  ls/la  sue-  B10.A:  Stir.1 fir 
ceptible and l/le  resistant.  Srlv-2 ~jr  H-2 "~°  76  60  10  P  < 0.010 (hypothe- 
It-2 "~°  sis rejected) 
F,:  Srlv-l'~" 
Srlv-2 "l"  1t-2 "l~a  75  64  14 
H-2 ~s~ 
two dominantly expressed loci (Srlv-1, Srlv-2) not linked to 1-1-2. The leukemia 
incidence predicted for each mode of inheritance can be computed by multiply- 
ing  the  expected  genotype frequency by  the  leukemia  incidence  previously 
observed for this genotype (see Table I).  For example, if it is assumed that a 
single, non-H-2-1inked locus confers susceptibility to RadLV, all possible 1-1-2 1092  NON-H-2  CONTROL  OF  RadLV-INDUCED  LEUKEMOGENESIS 
haplotypes, namely Yl/Yl, a/a, and yl/a, will be associated with genotypes s/s, 
s/r, and r/r at the non-H-2 locus (where s stands for the susceptible allele, and r 
for the resistant one) with a frequency of 0.25, 0.50, and 0.25, respectively. Only 
the r/r genotype will confer resistance, while the H-2 genotype ofF2 progeny will 
be irrelevant in determining resistance or susceptibility to RadLV. The leuke- 
mia  incidence  predicted  for  this  mode  of inheritance  may  be  computed  by 
mutiplying the expected genotype frequency by the leukemia incidence previ- 
ously observed for this genotype (in this case it is [(0.25 × 79%) +  (0.50 × 78%) + 
(0.25 ×  19%)] -- 64%). The difference between the expected and observed results 
for each mode of inheritance was analyzed by the X  2 test (16). 
Data presented in Table III suggest that a single, dominant locus, which is not 
linked  to Ho2  confers susceptibility to  RadLV.  We tentatively designate this 
locus, Srlv-1,  and assign two alleles, s  denoting susceptibility and r  denoting 
resistance.  (The possibility, not shown in Table III, that two genes are opera- 
tive, either one of which is sufficient to confer susceptibility, may also be ruled 
out by similar analysis.) 
The Locus Conferring Dominant Susceptibility to RadL V-Induced Leukemo- 
genesis is not Fv-2.  FV inoculation induces erythryoleukemia, the outstanding 
feature of which is a  logarithmic  increase in spleen weight, beginning almost 
immediately after virus inoculation  (7,  17). The splenomegaly results from the 
proliferation of erythrocyte precursor cells and is accompanied by the appear- 
ance of macroscopic foci on the surface of the spleen as early as 6-9 days after 
infection.  The component of FV capable of inducing  spleen foci is designated 
spleen focus-forming virus (SFFV). The host phenotype for SFFV is governed by 
the gene Fv-2, which has been mapped to chromosome 9. Fv-2 seems to play a 
negligible genetic role in governing the response of mice to leukemia viruses 
other than SFFV, probably because most other murine luekemia viruses infect 
nonerythroid  cells.  Therefore,  Fv-2  probably  does not  affect  RadLV-induced 
leukemogenesis.  However, although strain  AQR does not carry the transloca- 
tion maker,  it was derived from a  recombination event between strains B10.A 
and T138, a translocation stock (13) involving chromosomes 9 and 17. Since Fv-2 
is associated with chromosome 9 and confers dominant susceptibility, and since 
CBA which is Fv-2  ~ (susceptible) was one of the parent strains used in deriving 
T(2;9) 138Ca (14), the possibility that susceptibility to RadLV in B10.AQR(n4) is 
due to Fv-2 was investigated. 
FV  was  inoculated  at  various  dilutions  into  BALB/c  (Fv-2  ~,  susceptible), 
B10.A(1R) (Fv-2  r, resistant),  and B10.AQR(n4). Since B10.AQR(n4) appears to 
be as resistant as B10.A(1R) to splenomegaly and focus formation B10.AQR(n4) 
mice carry the Fv-2  ~ allele (Fig. 2). The Srlv-1 locus is thus distinct from the Fv- 
2  locus. 
Discussion 
B10.AQR(n4) mice are highly susceptible to RadLV-induced leukemogenesis 
despite carrying the H-2D ~ allele which has been shown to confer resistance to 
the disease (6). F2 segregation analysis and studies with B10.AQR(n8) strongly 
suggest that susceptibility is due to a locus not linked to the major histocompati- 
bility complex, H-2. In addition, susceptibility is inherited in dominant fashion, D.  MERUELO,  M.  LIEBERMAN,  B.  DEAK,  AND  H.  O.  McDEVITT 
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FIG.  2.  The  Fv-2  phenotype  of  B10.AQR(n4)  is  resistant.  NB-tropic  FV  was  injected 
intravenously at various dilutions,  and 9  days later mice were sacrificed,  their spleens 
weighed and then fixed  in Bouin's solution as  described under Materials  and Methods. 
BALB/c mice are Fv-2  s and are highly susceptible to SFFV, whereas B10.A(1R) mice are Fv- 
2" and highly resistant to SFFV. The B10.AQR(n4) mice are judged to be homozygous Fv-2  r 
since susceptibility is dominant. Each experimental point shown is the average of four mice 
individually tested. No animal in a  group significantly differed in spleen weight from the 
average value given. 
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whereas H-2Dd-linked  resistance to  RadLV-induced tumorigenesis is  domi- 
nantly expressed. The B10.AQR(n4) locus in question is notFv-2, norFv-1, since 
RadLV is a B-tropic virus (18) and would be expected to replicate well in C57BL/ 
10-derived  strains  (Fv-lb).  The  rapid  RadLV-induced  leukemogenesis  in 
B10.AQR(n4) mice, therefore, suggests that this strain is Fv-1 b. In addition, Fv- 
/-associated  resistance  is  dominantly  expressed.  The  locus  carried  by 
B10.AQR(n4) is designated Srlv-1, i.e., susceptibility to RadLV-1, in accordance 
with similar nomenclature used in defining loci conferring resistance to Gross 
virus, Rgv-1  and Rgv-2  [7]. 
The mechanism of action of Srlv-1  is presently unknown, although prelimi- 
nary data indicate that it might affect virus production. Supernates obtained 
from  B10.AQR(n4)-derived,  RadLV-induced tissue  culture  lines  have  15-20 
times as much reverse transcriptase activity per cell as  fluids derived from 
B10.G,  B10.S(7R),  B10.S(9R),  and B10.T(6R)  tissue culture-adapted, RadLV- 
induced, tumor cells (D.  Merue]o, unpublished observations). The latter four 
lines  are  derived from  strains  of mice with  similar  non-H-2  genetic back- 
grounds, and show comparable levels of reverse transcriptase activity. 
An important consideration is that the phenotypic expression of Srlv-1  can 
override the protection provided by H-2D d, since B10.AQR(n4)  and H-2D d are 
fully susceptible.  The latter is  also  true for  (B10.AQR  ×  B10.A)F2 progeny 
carrying the Srlv-l" and H-2D ~ from the B10.AQR(n4)  parent and the Srlv-1 r 
and H-2D d from the B10.A parent. 
These findings are suggestive of complex genetic interactions between distinct 
loci affecting virus-induced leukemogenesis. This is an area of great importance, 1094  NON-H-2  CONTROL  OF  RadLV-INDUCED  LEUKEMOGENESIS 
which  has  only  recently  begun  to  be  explored  (7,  19).  Further  studies  are 
currently in progress to understand the mechanism of action ofSrlv-1, as well as 
its precise genetic localization. 
Summary 
A  single locus,  tentatively denoted Srlv-1  (susceptibility to radiation  leuke- 
mia virus[RadLV]-l), confers dominant susceptibility to RadLV-induced leuke- 
mogenesis. Srlv-1  is not linked to H-2, and appears to be distinct from Fv-1 and 
Fv-2. Preliminary data suggest that Srlv-1 affects virus proliferation. A striking 
feature of this system is that Srlv-1  overrides the protection afforded by the H- 
2D-associated dominant resistance to RadLV-induced neoplasia. 
We  are  most  grateful to  Nancy  Ginzton  and  Diane  Teece  for their excellent technical 
assistance  during  this  work, and  to  Dr. Theodore Pincus for  helpful  suggestions in  assaying  for  Fv- 
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